zepbound kwikpen - Search News

Eli Lilly, Zepbound

Eli Lilly launches new weight-loss drug Zepbound KwikPen: What to know

Drug maker Eli Lilly says data from a late-stage trial showed a reduction in weight of almost 8% in people with Type 2 diabetes.

· 1d · on MSN

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

ConsumerAffairs · 1d

FDA approves four-dose Zepbound KwikPen for weight loss

· 2d

Novo Nordisk’s stock closes at 4-year low after its next-gen weight-loss drug lost to Lilly’s in Phase 3 trial

Novo Nordisk says a study found its experimental next-generation drug didn’t reduce as much weight as Eli Lilly’s Zepbound.

· 1d

Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades

· 1d

These Stocks Are Today’s Movers: Novo Nordisk, Lilly, PayPal, Arcellx, CrowdStrike, KKR, Strategy, and More

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device.

12h

Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact

On February 24, BofA said Novo Nordisk’s decision to cut GLP-1 list prices may draw attention, but the firm does not expect a meaningful impact on the US market.